Pfizer wins full FDA approval for Braftovi in colorectal cancer

Pfizer (PFE) stock is in focus as the FDA grants full approval for its colorectal cancer drug Braftovi, developed with Ono Pharmaceutical (OPHLF). Read more here.
Yahoo

FDA approves meningioma label warning on Pfizer’s contraceptive injection

Add Yahoo as a preferred source to see more of our stories on Google. The FDA has approved a label change to Pfizer's contraceptive injection The US Food and Drug Administration (FDA) has approved a ...
PharmiWeb

U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...
Benzinga.com

FDA Approves Brain Tumor Warning For Pfizer's Depo-Provera Amid Lawsuit

The U.S. Food and Drug Administration (FDA) has approved a label change for Pfizer Inc.'s (NYSE: PFE) Depo-Provera contraceptive injection, adding a warning about the risk of meningioma, a type of ...

Pfizer wins FDA priority review for Hympavzi label expansion

Pfizer (PFE) announced on Friday that the U.S. Food and Drug Administration granted priority review for a marketing application seeking a label expansion for its hemophilia therapy, Hympavzi. The New ...